Epkinly/Epcoritamab (GEN3013) (CD3-CD20 Bispecific)

2026-05-21 — Genmab A/S (Nasdaq: GMAB) announced it will present or publish 23 abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago) and the 2026 EHA Congress (June 11–14, Stockholm). Twenty abstracts focus on epcoritamab, a subcutaneous CD3xCD20 T‑cell–engaging bispecific antibody (marketed as EPKINLY/TEPKINLY for certain lymphoma indications), including four oral presentations.

Key disclosures include full Phase 3 EPCORE DLBCL‑1 results comparing epcoritamab monotherapy vs investigator’s choice chemoimmunotherapy in relapsed/refractory large B‑cell lymphoma, and additional Phase 3 EPCORE FL‑1 data evaluating epcoritamab plus rituximab/lenalidomide (R²) vs R² in relapsed/refractory follicular lymphoma. The program also includes outcomes across monotherapy, combinations, fixed-duration use, outpatient administration, earlier-line treatment, plus real‑world and health economics analyses.

Three additional abstracts cover ongoing trial evaluations of Genmab’s late-stage investigational agents rinatabart sesutecan (Rina‑S; FRα‑targeted ADC; Phase 3 RAINFOL studies) and petosemtamab (EGFR/LGR5 bispecific; Phase 2 with pembrolizumab in PD‑L1–high metastatic NSCLC).